Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
| 3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
| 2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
| 1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
| 9/14/2022 | $40.00 | Outperform | SVB Leerink |
| 9/9/2022 | $15.00 | Underweight | Morgan Stanley |
| 3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
144 - Vir Biotechnology, Inc. (0001706431) (Subject)